Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.56 USD | +2.22% | +5.45% | -9.67% |
05-14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
05-13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.67% | 479M | |
+8.22% | 114B | |
+9.79% | 104B | |
-1.83% | 22.57B | |
-11.30% | 22.5B | |
-10.39% | 17.95B | |
-41.90% | 16.48B | |
-14.29% | 15.82B | |
+3.90% | 13.55B | |
+28.96% | 10.99B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $18.8M, vs. Street Est of $21.4M